Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
토요일, 8월 22

Guardant Health Inc

GHNASDAQ
Trade with Public
Trade with Public
$170.69
2.811.67%
가까이에: Aug 21, 5:00 PM EST
$170.65
-0.04-0.02%
시간외: 6:55 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Guardant Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for Guardant Health (GH).

Price Target Range — 7 Quarters

Analyst Consensus — 24 Analysts

24Buy
Consensus RatingBuy# Analysts24Avg. Consensus PT$154Upside to Avg. PT-9.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Piper SandlerDavid WestenbergPT RaiseOverweight$135→$193
Aug 4, 2026Stephens & Co.Mason CarricoPT RaiseOverweight$170→$195
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193

Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
Benzinga Newsdesk

PRO
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195

Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185

Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
Benzinga Newsdesk

PRO
Stifel Maintains Buy on Guardant Health, Raises Price Target to $180

Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200

RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200

Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved